An


Journal

Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410

Informations de publication

Date de publication:
04 2022
Historique:
received: 11 03 2021
revised: 29 06 2021
pubmed: 31 7 2021
medline: 5 4 2022
entrez: 30 7 2021
Statut: ppublish

Résumé

The short half-life of existing prostate-specific membrane antigen (PSMA) tracers limits their time for internalization into tumor cells after injection, which is an essential prerequisite for robust detection of tumor lesions with low PSMA expression on PET/CT scans. Because of its longer half-life, the

Identifiants

pubmed: 34326129
pii: jnumed.121.262290
doi: 10.2967/jnumed.121.262290
doi:

Substances chimiques

Androgen Antagonists 0
Gallium Isotopes 0
Gallium Radioisotopes 0
gallium 68 PSMA-11 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

573-583

Informations de copyright

© 2022 by the Society of Nuclear Medicine and Molecular Imaging.

Auteurs

Felix Dietlein (F)

Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany.
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Carsten Kobe (C)

Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany.

Sergio Muñoz Vázquez (SM)

Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany.

Thomas Fischer (T)

Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany.

Heike Endepols (H)

Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany.
Institute of Radiochemistry and Experimental Molecular Imaging, University Hospital of Cologne, Cologne, Germany.

Melanie Hohberg (M)

Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany.

Manuel Reifegerst (M)

Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany.

Bernd Neumaier (B)

Institute of Radiochemistry and Experimental Molecular Imaging, University Hospital of Cologne, Cologne, Germany.
Institute of Neuroscience and Medicine, INM-5 (Radiochemistry), Forschungszentrum Jülich GmbH, Jülich, Germany; and.

Klaus Schomäcker (K)

Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany.

Alexander E Drzezga (AE)

Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany.
Institute of Neuroscience and Medicine, INM-2, Forschungszentrum Jülich GmbH, Jülich, Germany.

Markus Dietlein (M)

Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany; markus.dietlein@uk-koeln.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH